Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02907281 · ClinicalTrials.gov registry record

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis

A clinical trial of Multiple Sclerosis and RRMS, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
414
Enrollment target
20
Study locations

NCT02907281 is a study of Multiple Sclerosis and RRMS that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 414 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02907281, a study of Multiple Sclerosis and RRMS, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
414 participants
Enrollment target
20
Study locations

Study Summary

This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome measure in patients with relapsing remitting multiple sclerosis (RRMS). Approximately 350 RRMS patients, either untreated or treated with an approved MS disease-modifying therapy and approximately 70 reference subjects without ophthalmologic or neurologic disease are enrolled. No study medications are provided. Patients on disease-modifying therapy are treated according to the local prescribing information. For each MS patient and each reference subject, the study consists of Screening (up to 1 month), Baseline, and a 36-month longitudinal data collection phase. Eligibility will be confirmed during Screening.

Conditions Studied

Multiple Sclerosis RRMS

Interventions

  • OTHER Observational

Study Locations (20)

Other

  • Novartis Investigative Site - Prague
  • Novartis Investigative Site - Copenhagen
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Magdeburg
  • Novartis Investigative Site - Bari
  • Novartis Investigative Site - Genova
  • Novartis Investigative Site - Montichiari
  • Novartis Investigative Site - Padua
  • Novartis Investigative Site - Roma

California

  • Novartis Investigative Site - San Francisco
  • Novartis Investigative Site - Torrance

Iowa

  • Novartis Investigative Site - Iowa City

Maryland

  • Novartis Investigative Site - Baltimore

Pennsylvania

  • Novartis Investigative Site - Philadelphia

New South Wales

  • Novartis Investigative Site - Camperdown

Victoria

  • Novartis Investigative Site - Parkville

Alberta

  • Novartis Investigative Site - Calgary

Trial Details

FieldValue
Enrollment Target 414 participants
Start Date 2012-05-29
Est. Completion 2017-07-24

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02907281

The ClinicalTrials.gov registry entry for NCT02907281 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (29% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.

NCT02907281 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Iowa.

Frequently Asked Questions

What is clinical trial NCT02907281 about?

NCT02907281 is a clinical study titled "Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis". This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome measure in patients with relapsing remitting multiple sclerosis (RRMS). Approximately 350 RRMS patients, either untreated or treated with an approved MS disease-modifying therapy and approximately 70 referenc...

What is the current status of trial NCT02907281?

This trial is currently completed. The enrollment target is 414 participants. The study started on 2012-05-29. Estimated completion is 2017-07-24.

What conditions does trial NCT02907281 study?

This clinical trial studies the following conditions: Multiple Sclerosis, RRMS.

What interventions are being tested in trial NCT02907281?

The interventions under investigation include: Observational (OTHER).

Who is sponsoring clinical trial NCT02907281?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02907281 being conducted?

This trial has 20 study locations across California, Iowa, Maryland, Pennsylvania, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

RRMS

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.